272 filings
8-K
VNDA
Vanda Pharmaceuticals Inc
8 May 24
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
4:06pm
8-K
VNDA
Vanda Pharmaceuticals Inc
7 May 24
Other Events
4:51pm
8-K
VNDA
Vanda Pharmaceuticals Inc
3 May 24
Entry into a Material Definitive Agreement
4:02pm
8-K
VNDA
Vanda Pharmaceuticals Inc
17 Apr 24
Entry into a Material Definitive Agreement
5:19pm
8-K
VNDA
Vanda Pharmaceuticals Inc
3 Apr 24
Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval
4:32pm
8-K
whruip84uqdrcdc9
7 Mar 24
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
4:31pm
8-K
3jj5y94o04
21 Feb 24
Departure of Directors or Certain Officers
4:32pm
8-K/A
z2m0d2
16 Feb 24
Special Purpose Abbreviated Financial Statements
4:31pm
8-K
72pk oqvk
7 Feb 24
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
4:07pm
8-K
w1vd672 yh9
5 Feb 24
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
4:34pm
8-K
y0daeo
15 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
k03l8s9b5 zw
7 Dec 23
Entry into a Material Definitive Agreement
5:19pm
8-K
tnqdc4rcm3ik ue
8 Nov 23
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
4:05pm
8-K
qmm2 s3m3eg9e1i64
21 Aug 23
Other Events
5:13pm
8-K
g033fqpw3
27 Jul 23
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
4:06pm
8-K
p0zdo5o39efbn5
8 Jun 23
Submission of Matters to a Vote of Security Holders
4:40pm
8-K
84q4 a69lp6t0b
11 May 23
Other Events
7:01am
8-K
z8eaxtw
3 May 23
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
4:05pm
8-K
a3bx4n2lc4j4
17 Mar 23
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
7:05am
8-K
vei hipf4xm
13 Mar 23
Regulation FD Disclosure
9:25am